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Patients with human papillomavirus- (HPV-) related oropharyngeal squamous cell carcinoma (OPSCC) have a better prognosis
than HPV-negative OPSCC when treated with standard high-dose cisplatin-based chemoradiotherapy. Consistent with this
assertion and due to younger age at diagnosis, novel approaches tominimize treatment sequelaewhile preserving survival outcomes
become of paramount importance. Here, we critically reviewed the evidence-based literature supporting the deintensification
strategies in HPV-related OPSCC management, including radiotherapy dose and/or volume reduction, replacement of cisplatin
radiosensitising chemotherapy, and the use of transoral surgery. Undoubtedly, further researches are needed before changing the
standard of care in this setting of patients.
1. Introduction
Despite oropharyngeal squamous cell carcinoma (OPSCC)
representing only 0.9% of all cancer sites, its incidence is
rapidly growing worldwide, with an estimated 173,495 new
cases in 2018 [1]. The highest incidence rates are seen in
the western countries [2]. During the past two decades
OPSCC diagnosis increased among men and/or women
in different European nations, such as United Kingdom,
France, Germany, Denmark, and Sweden [2, 3]. The main
reason is oncogenic human papillomavirus (HPV) type
16 infection and nowadays HPV-related OPSCC, primarily
located in tonsil and base of tongue, is considered a distinct
disease entity [4]. Patients with HPV-related OPSCC have
a much better prognosis than those with tobacco/alcohol-
driven disease, despite a higher stage at diagnosis due to
a typical small primary in the oropharynx with massive
regional nodal involvement. Compared with HPV-negative
OPSCC, HPV-related OPSCC affects younger patients with
a lower comorbidity index, a higher socioeconomic status,
and a history of multiple sexual partners and orogenital
sexual practice [5]. Intensity modulated radiation therapy
with concurrent cisplatin-based chemotherapy represents
the standard treatment, when appropriate. This definitive
chemoradiotherapy (CRT) approach aims to eradicate tumor
cells and minimize both acute and late toxicities. Given
the favorable prognosis in a younger patient cohort, novel
treatment regimens with the same tumor control and lower
toxicity rates are a welcome change.
Here, we presented a critical review of recent advances
in the management of HPV-related OPSCC. We focused on
the existing literature regarding the proposal applications of
radiation therapy and systemic therapy. An assessment of new
staging system specifically for HPV-related OPSCC and its
development was also reported.
2. Materials and Methods
Key HPV-related OPSCC references were derived from a
systematic PubMed query. Articles were obtained using
the following combinations of research criteria: “inten-
sity modulated radiotherapy”, “imrt”, “radiation therapy”,
“de-intensification”, de-escalation”, “immune check-point
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Table 1: Independent external validation of the 8th edition staging of HPV-related oropharyngeal cancer.
5-y OS by 8th edition TNM stage
Author Year of publication Patients Primary treatment I II III IV
O’Sullivan [6] 2016 1907 S: 34; RT: 1873 85% 78% 53% NA
Haughey [7] 2016 704 S: 704 90% 84% 48% NA
Cramer [8] 2017 15116 S: 6465; RT: 7841; CHT: 276 87.4%∗ 76.6%∗ 63.1%∗ 20.7%∗
Malm [9] 2017 435 S: 166; RT: 269 92.3% 87.2% 73.6% 40.0%
Porceddu [10] 2017 279 RT: 279 93.6% 81.9% 69.1% NA
international collaboration on oropharyngeal cancer network for staging (ICON-S) study
∗4-year overall survival
5-y OS: 5-year overall survival; S: surgery; RT: radiotherapy; CHT: chemotherapy; NA: not applicable





361 articles excluded because of
different subject
5 no English; 30 review; 5 duplicate
articles; 10 editorial 
6 excluded because old version of
updated manuscript
Figure 1: Literature search.
inhibitors”, “cetuximab”, “cisplatin”, “platinum”, “toxicity”,
“quality of life”, “chemotherapy”, “induction”, “treatment”,
“transoral surgery”, “tors”, “hpv”, “head and neck cancer”,
“oropharyngeal”, “oropharynx” (Figure 1). Hand searching
(meeting proceedings of European Society ofMedical Oncol-
ogy, European SocieTy for Radiotherapy &Oncology, Ameri-
can Society for Radiation Oncology and American Society of
Clinical Oncology) and clinicaltrials.gov were also used. The
last literature search was done in January 2019. Only English
written publications were selected. Titles and abstracts of
search results were screened to determine eligibility in the
manuscript.
3. Results
3.1. New Classification System for HPV-Related Oropha-
ryngeal Cancer. The 8th edition American joint commit-
tee on cancer (AJCC) tumor, lymph node, and metasta-
sis (TNM) staging manual on OPSCC introduced signifi-
cant modifications from the prior 7th edition [11]. HPV-
related OPSCC—based on the overexpression of the cyclin-
dependent kinase p16—was part of a separate section. It
specifically resulted in a change of T and N categories, due
to the important need to discriminate between the different
stage groups compared to OPSCC associated to other causes.
HPV-related OPSCC clinical (c) T classification no longer
included a cT4b category, because 5-year overall survival was
similar for patients classed as cT4a and cT4b according to
7th edition TNM staging system [6]. N classification, both
clinical and pathological (p), represented the main change
from the tobacco/alcohol-drivenOPSCC. Because cN1, cN2a,
and cN2b (7th edition TNM) cohorts had similar impact
on 5-year survival, they were grouped as one cN1 category,
including ≥ 1 ipsilateral lymph nodes, none larger than 6 cm
whereas cN2c was reserved for contralateral or bilateral
lymph nodes, none larger than 6 cm, and cN3 included ≥
1 lymph nodes larger than 6 cm. The combination of cT
and cN into stages—stage I (cT1-2 cN0-1), stage II (cT1-2
cN2 or cT3N0-2), and stage III (cT4 or cN3)—depicted an
adequate discrimination in HPV-related OPSCC prognosis
groups. Interestingly only distant metastatic disease (M1) was
considered stage IV.
The rationale for these changes is based on the inter-
national collaboration on oropharyngeal cancer network for
staging (ICON-S) multicentre cohort study, including 1907
patients with HPV-related OPSCC from seven institutions
across Europe and North America [6]. Several independent
external validations have been proposed [7–10]. Details are
listed in Table 1. Results showed similar or even better 5-
years overall survival ratesweighed against the ICON-S study.
Globally, these cohorts confirmed that the new classification
in HPV-related OPSCC provided better survival discrimina-
tion across the different stage categories compared to the 7th
edition TNM. Several considerations should be addressed.
Firstly, this favorable effect could be mainly driven by the
high treatment strategy (surgery and/or CRT). An illustrative
example included cT2cN1 disease, now stage I (8th edition
TNM) and previously stage III (7th edition TNM).Therefore,
it remains unknown whether the high survival rate observed
in HPV-related OPSCC patients represents an effective good
prognosis factor or merely reflects an overtreatment in this
population. Secondly, other factors, such as age, smoke, and
alcohol, may potentially even better stratify this setting of
patients.
pN categories focused only on number of positive lymph
nodes, using a cut-off of 4 to discriminate between pN1
(≤ 4 positive lymph nodes) and pN2 (> 4 positive lymph
nodes). Pathologic data emerged from surgical HPV-related
OPSCC cohort of 704 patients from five cancer centers [7].
It should be noted that the presence of bilateral/contralateral
lymph nodes had prognostic impact (p=0.049) in the uni-
variate analysis for overall survival, as well as extranodal
extension (ENE) having a positive trend (p=0.060). An
Journal of Oncology 3
external validation, based on 3745 patients from the national
cancer database (NCDB), concluded that ENE could play a
prognostic role in HPV-related OPSCC [12]. Results showed
a significant negative ENE effect (p < 0.001) on survival. But
this effect remained statistically significant when stratified
by N-stage only for pN1 disease. Further studies with large
cohort of patients are necessary to validate these patholog-
ical changes. But, again, maybe, to improve discrimination
between pathological groups, more factors, such as bilater-
ally/contralaterally and ENE, should be considered.
3.2. Radiation Therapy in HPV-Related Oropharyngeal Can-
cer. When appropriate, definitive cisplatin-based CRT using
intensity modulated technique (IMRT) is the standard of care
in OPSCC. But this approach has drawbacks in terms of
toxicity and subsequent patient quality of life (QoL). Consid-
ering the good prognostic value of HPV-driven disease, novel
treatment paradigms have been proposed in HPV-related
OPSCC. These treatment strategies include (i) radiation
dose deescalation, (ii) radiation volume deescalation, (iii)
induction response-based therapy, (iv) transoral surgery and
deintensification of adjuvant treatment. The joint aim is to
determine whether a less intensive regimen could minimize
toxicity while maintaining similar cure rates.
Radiation Dose Deescalation. Late RT-related toxicity repre-
sents a significant burden to OPSCC survivors, because it
negatively impacts on their QoL and their ability to function
in society. The dose delivered to surrounding tissues plays
a crucial role in the development of late toxicity. A dose-
effect relationship between dose exposure—maximum dose
(Dmax) and/or mean dose (Dmean) and/or percentage of
volume receiving x Gy (Vx)—of a specific organ at risk
(OAR) and development of its related toxicity has been
well established. For instance, a Dmean greater than 50Gy
to pharyngeal constrictor muscles, a Dmean greater than
26Gy to parotid gland, and a V50 greater than 40.5%
to mandible can, respectively, cause moderate to severe
swallowing impairment, xerostomia, and osteoradionecrosis
[13–15]. Ideally each OAR in the head and neck region
should receive a low dose exposure to reduce the risk of
RT-induced toxicity. But, in OPSCC, RT with curative intent
requires large treatment fields and high doses to be effective.
Traditionally the total dose delivered to eradicate clinical and
subclinical disease is 70Gy (2Gy per fraction) and 50Gy
(2Gy per fraction), respectively. Therefore it is not always
feasible to respect all OARs dose constraints, especially for
those structures in close proximity to burden tumor, such
as dysphagia-related structures, parotid gland, and mandible.
Given the IMRT technical ability (that permits including
OARs in the optimization process) and the low incidence
of regional failures in the elective volume (that receives a
prophylactic dose of 50Gy), deintensification RT strategies
could result in toxicity reduction without compromising sur-
vival outcomes [16, 17]. Radiation dose deescalation strategies
are currently under investigation. A phase III randomized
clinical trial was performed to evaluate the dose reduction
effect on late toxicity and regional tumor control in head
and neck cancer patients [18]. Independently of HPV status,
200 patients with head and neck carcinoma were randomized
to the standard dose of 50Gy versus the experimental dose
of 40Gy prescribed to the elective nodal volumes. Primary
end-point was dysphagia at 6 months of follow-up. Results
showed a trend to less dysphagia (p = 0.02) and less salivary
gland toxicity (p = 0.01) at 6 months without differences in
overall, disease-free, and disease-specific survival, as well as
local, regional, and distant control. But absolute numbers of
regional recurrences and distant metastases were too small to
draw definitive conclusions on the safety of dose deescalation
to 40Gy to the elective nodal volume. For sure it represents an
interesting approach especially in the context of HPV-related
OPSCC, due to the long life expectancy of a patient once his
cancer is cured.
Aparallel betweenHPV-relatedOPSCCandHPV-related
anal canal carcinoma could be even more interesting. In fact,
these two malignancies presented similar tumor histology
and viral etiology. A main consideration can be made in
the context of organ preservation strategy, using combined
CRT modality. In anal canal carcinoma, a total dose of
59.4Gy (1.8Gy per fraction) with concurrent chemotherapy
is recommended to assure a curative intent [19]. Therefore
it could be reasonable to prescribe a lower radiation dose
(≤ 60Gy) plus concomitant chemotherapy in the treatment
of HPV-related OPSCC. It might result in similar clinical
outcomes decreasing toxicity rates. Evidence is accumulating
that radiation dose deescalation can refer to primary tumor
target volume [20]. In a phase II trial, 43 favorable risk
HPV-related OPSCC patients were treated with IMRT to
a total dose of 60Gy (2Gy per fraction) plus concomitant
weekly cisplatin (30mg/m2 per week). Compared to standard
CRT regimen, radiation dose was reduced by 16% (70 to
60Gy) and cumulative chemotherapy dosage was reduced
by 60% (300mg/m2 to 180mg/m2). Primary end-point was
pathological complete response (pCR) based on biopsy of
the primary site and a limited or selective neck dissection
of pretreatment positive lymph node regions. This allowed
for a more patient safety standpoint due to authors being
worried for detrimental outcomes of deintensified strategy.
The pCR rate was 86% with relatively decreased toxicity.
Globally results were encouraging, but a randomized clinical
trial to make a direct comparison to standard regimen is
paramount to assess the real impact of deintensified CRT on
both long-term tumor control and toxicities.
Recently, the Memorial Sloan-Kettering Cancer Cen-
ter group performed a pilot study to test hypoxia imag-
ing—18F-fluorodeoxyglucose (18F-FDG) and dynamic 18F-
fluoromisonidazole (18F-FMISO) positron emission tomog-
raphy (PET)—as selection criteria for radiation dose deesca-
lation to gross nodal disease in HPV-related OPSCC patients
[21]. Stages III-IVb HPV-related OPSCC (7th edition)
patients without pretreatment hypoxia or with resolution
of hypoxia within 1 week of treatment on intratreatment
18F-FMISO PET received a 10Gy dose reduction (from
70Gy to 60Gy) to either the primary site and/or lymph
node(s). Of the 33 patients enrolled, 10 patients (30%) met
the criteria for radiation dose deescalation. At a median
follow-up of 32 months, the 2-year locoregional control,
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overall survival, and distant metastasis-free survival were
100%, 100%, and 97%, respectively, with minimal toxicity.
This approach emphasized the potential role of 18F-FMISO
PET to guide therapeutic decisions, but further studies are
necessary.
Several studies attested the high radiosensitivity of HPV-
related OPSCC, reporting comparable clinical outcomes in
patients with HPV-positive head and neck cancer treated
with definitive RT alone instead of standard CRT [22–24].
The reported influence of tumor HPV-status on RT respon-
siveness should be considered in radiation dose deescala-
tion strategies, even though exactly how to individualized
treatment remains uncertain. In this context, the NRG
Oncology cooperative group is leading a randomized phase
II trial (NCT02254278) to test exclusive modestly reduced-
dose IMRT (60Gy, 2.4Gy per fraction) versus CRT (weekly
40mg/m2 cisplatin and 60Gy, 2Gy per fraction) in 296
planned patients with cT1-2, cN1-2b, or cT3, N0-2b (7th
edition) HPV-related OPSCC and a lifetime cumulative
smoking history < 10 pack-years [25].
Radiation Volume Deescalation. Several investigators
assumed that limited radiation to the ipsilateral neck without
compromising locoregional control could be feasible in
selected patients also in the HPV era [26–30]. In general,
elective neck irradiation is not recommended if subclinical
disease risk is < 10%, due to RT morbidity [29]. Compared
to bilateral irradiation, unilateral neck irradiation permitted
to better spare OARs and reduce the risk of RT-related side
effects, such as xerostomia, improving patients’ QoL [26]. A
recent publication showed that ipsilateral RT continued to be
safe and contralateral neck failure remained low for patients
with cT1-2 cN0-2b (7th edition) HPV-related tonsillar cancer
[30]. With regard to control of lymphatic spread, a careful
case selection—well-lateralized lesion, without extension to
soft palate or tongue base, without muscle involvement or
any suspicion of deeper penetration, and no contralateral
neck lymph node metastasis— become essential. Prospective
clinical trials addressing the suitability of ipsilateral radiation
in HPV-related OPSCC are warranted to confirm the
efficacy of this approach. Restaging of HPV-related OPSCC
series according to 8th edition TNM and reevaluation of
previous treatment indications could result in a change of
the therapeutic strategies for HPV-related OPSCC. Probably
radiation volume deescalation is only imaginable in low-risk
HPV-positive patients.
Induction Response-Based Therapy. Different groups have
pursued an approach of radiation dose deescalation following
the use of induction chemotherapy [31–35].
The Optima trial was a phase II deescalation study
designed for patients with HPV-related OPSCC [31]. Induc-
tion chemotherapy was adopted to identify favorable patients
to apply significantly lower (chemo) radiation doses than
standard CRT. Patients were classified as low-risk (≤ T3,
≤ N2b, ≤ 10 pack-year history) and high-risk (T4 or ≥
N2c or >10 pack-year history). They received induction
chemotherapy, including 3 cycles of carboplatin (AUC 6) and
nab-paclitaxel (100mg/m2). Based on response to induction
treatment, locoregional therapy was stratified as (i) low-
dose RT alone to 50Gy (2Gy per fraction) in low-risk
patients with ≥ 50% response, (ii) low-dose CRT to 45Gy
(1.5Gy twice-daily fraction and paclitaxel, 5-fluorouracil, and
hydroxyurea) in low-risk patients with 30-50% response or
high-risk patients with ≥ 50% response, (iii) standard-dose
CRT to 75Gy (1.5Gy twice-daily fraction and paclitaxel,
5-fluorouracil, and hydroxyurea) in poor responders. Pri-
mary site biopsy and neck dissection were performed only
after deescalated (C)RT for pathologic confirmation. The
primary endpoint was 2-year progression-free survival (2-
y PFS). With a median follow-up of 29 months, the 62
patients enrolled achieved excellent 2-y PFS rates (95% for
low risk patients, 94% for high risk patients). Severe acute
toxicity, including oral mucositis, skin dermatitis, and PEG-
tube requirement, was significantly lower with deescalated
treatment. These results compare favorably to the historical
control and justified the evaluation of this strategy in a larger
comparative trial. But it should be noticed that standard-dose
CRT scheme—1.5 Gy twice-daily fraction and paclitaxel, 5-
fluorouracil, and hydroxyurea—differed from the standard of
care cisplatin-based CRT treatment.
Similarly, the ECOG-ACRIN Cancer Research Group
trial evaluated induction chemotherapy (cisplatin, paclitaxel,
and cetuximab) followed by concurrent cetuximab and RT to
54Gy (2Gy per fraction), complete responders, or 69.3Gy
(2.1Gy per fraction), no-complete responders, in HPV-
related OPSCC patients [32]. The primary end-point was 2-
y PFS. Globally, 80 patients were evaluated. After a median
follow-up of 35.4 months, 2-y PFS was 80% in cohort with
clinical complete response. Interestingly, treatment failures
occurred within 2 years after accrual and were recorded on
patients with a > 10 pack-year smoking history. Significantly
fewer patients treated with dose deescalation had difficulty
swallowing solids or impaired nutrition.
Another ongoing US single-arm phase II trial inves-
tigated whether weekly paclitaxel CRT with radiation
dose deescalation would maintain survival outcomes while
improving functional outcomes [33]. After two cycles of
paclitaxel/carboplatin-based induction chemotherapy, com-
plete or partial responders received 54Gy (2Gy per fraction)
and those with less than partial or no responses received
60Gy (2Gy per fraction). The primary endpoint was 2-y
PFS. A total of 45 patients with stages III-IV (7th edition)
HPV-relatedOPSCCwere enrolled.Median follow-upwas 30
months and 2-y PFS rate was 92% with an acceptable toxicity
profile.
The Quarterback is an active phase III trial that directly
compared a radiation dose deescalation to the standard of
care in HPV-positive patients [34]. After 3 cycles of docetaxel
cisplatin and 5-fluorouracil induction chemotherapy, patients
with a clinical or radiographic complete/partial response are
randomized to receive a reduced (56Gy) or standard (70Gy)
dose RT with weekly carboplatin. A total of 365 patients
with advancedHPV-related oropharynx cancer, nasopharynx
cancer, or unknown primary are planned to determine the
comparative rate of PFS at 3 years. Preliminary results—based
on 23 patients enrolled and 20 randomized–have been pre-
sented at ASCO meeting in 2017 and the 2-y PFS rates were
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87.5% for those patients receiving standard dose and 83.3%
for those patients receiving dose deescalation [35].
Globally, all these studies indicated that HPV-related
OPSCC could be successfully treated with a sequential
treatment strategy of induction chemotherapy followed by
radiation dose deescalation preserving both clinical and
functional outcomes.Definitive phase III randomized clinical
trials adopting the 8th edition TNM classification and stan-
dard of care treatment arm are paramount to confirm these
results, define appropriate candidates, and alter standard
clinical practice. Surely, independently of radiation treat-
ment modalities—dose deescalation, volume deescalation,
and following induction chemotherapy—the high-quality RT
is paramount to guarantee reliable treatment outcome.
Transoral Surgery and Deintensification of Adjuvant Treat-
ment. Adjuvant (C)RT dose reduction following primary
transoral surgery is also being proposed as an alternative
deescalation treatment strategy for HPV-related OPSCC. Its
main advantage is the proper adjuvant treatment based on
objective criteria driven by pathologic staging. To our knowl-
edge, there are as yet no published prospective randomized
data on this topic, but several clinical trials are ongoing [36–
41]. Actually, the Mayo Clinic group presented at ASTRO
2017meeting the results of the phase II MC1273 trial but full-
text is still not available [36]. This study included patients
with HPV-related OPSCC and ≤ 10 pack-year smoking
history. Following surgery with negative margins, patients
with ≥T3, ≥N2, lymphovascular invasion, or perineural
invasion received 30Gy (1.5Gy twice daily fraction) with
concomitant docetaxel. In case of evidence of extracapsular
spread, patients received the same treatment plus a simul-
taneous integrated boost to nodal levels with extracapsular
spread to 36Gy (1.8Gy twice daily fraction). Results showed
a locoregional control rate (95%) comparable to historical
controls. No patients required feeding tube. Based on these
data, a phase III multicenter study (DART-HPV trial) has
been designed and is actively accruing [37]. A total of 214
are planned. Patients are randomized to receive deescalated
adjuvant docetaxel-based CRT (30Gy in 1.5 Gy fractions
twice daily in intermediate risk patients or 36Gy in 1.8 Gy
fractions twice daily in high risk patients) versus standard of
care treatment with weekly cisplatin 40mg/m2 concomitant
to RT to 60Gy delivered in 2Gy per fraction. Primary end-
point is adverse events rate at 2 years.
The ECOG-ACRIN Cancer Research Group designed a
phase II trial for stages III-IVb HPV-related OPSCC [38].
cN0 patients are not eligible. Based on their risk status —low
risk: no adverse pathological features, intermediate risk:
T1-3, N2a-2b, perineural and/or vascular invasion or close
margins, and high risk: positivemargins and/or extracapsular
spread—patients are assigned to (i) transoral robotic surgery
(TORS) alone (low risk), (ii) TORS and low-dose RT, 50Gy
2Gy per fraction (intermediate risk), (iii) TORS and standard
dose RT, 60Gy 2Gy per fraction (intermediate risk), and
(iv) TORS and standard dose weekly platinum-based CRT,
66Gy 2Gy per fraction (high risk). Patients classified as
intermediate risk are randomized to low-dose or standard
dose treatment arm. Primary end-point is 2-y PFS.
In the ADEPT trial, HPV-related OPSCC patients
received either RT alone (60Gy, 2 Gy per fraction) or weekly
cisplatinum-based CRT (60Gy, 2 Gy per fraction) after
margin-clearing TORS of their T1-4a oropharynx primary
(7th edition) and a neck dissection with extracapsular spread
in their lymph nodes [39]. Primary end-points were 5-year
disease-free survival and 5-year locoregional control.
The primary outcome of the prospective randomized
PATHOS study is to improve patient-reported swallowing
outcome testing adjuvant dose deescalation RT in order to
continue to a phase III noninferiority study with overall
survival as the primary end-point [40]. Patients with stage
T1-3, N0-2b (7th edition) HPV-related OPSCC, are enrolled.
Following surgery and based on pathological risk factors for
recurrence, patients will receive (i) no adjuvant treatment, (ii)
randomization to adjuvant RT to 60Gy (2Gy per fraction) or
50Gy (2Gy per fraction), and (iii) randomization to adjuvant
weekly cisplatin-based CRT to 60Gy (2Gy per fraction) or
RT alone to 60Gy (2Gy per fraction).
An interesting approach was proposed by the Memorial
Sloan Kettering Cancer Center [41]. Investigators conducted
a pilot study using 18F- FMISO PET to identify HPV-related
OPSCC patients eligible for adjuvant dose deescalation.
Patients received surgery to primary tumor only, whereas
lymph nodes were evaluated by 18F- FMISO PET. Patients
without hypoxia or with resolution at intratreatment 18F-
FMISO PET received 30Gy (2Gy per fraction) to the tumor
bed and neck with 2 cycles of concurrent high-dose cis-
platin or carboplatin/5-FU. Patients with persistent hypoxia
received standard CRT up to 70Gy. Neck dissection was
performed 4 months after CRT. In total 19 patients were
enrolled and 15 patients were deescalated to 30Gy. Globally,
18 out of 19 patients (95%) remain disease free. A multicenter
trial to validate these pilot results is ongoing.
In summary, waiting for definitive results of the proposed
trials, no firm conclusions can be drawn. We agree with
the principle of pathological risk and functional imaging
assessment to guide treatment deescalation decisions.
3.3. Systemic Therapy in HPV-Related Oropharyngeal Cancer.
Efforts to minimize acute and late toxicity of primary CRT in
HPV-related OPSCC patients also include systemic therapy.
The options are (i) replacing cisplatin with the epidermal
growth factor receptor (EGFR) inhibitor cetuximab and (ii)
replacing cisplatin with immune check-point inhibitors.
ReplaceCisplatinwithCetuximab.Cetuximab is an IgG1mon-
oclonal antibody against the EGFR approved by the US Food
and Drug Administration in 2006 due to its proven survival
benefit (median survival from 29.3 months to 49 months)
without increasing the common toxic effects compared to
RT alone in locally advanced head and neck cancer (IMCL-
9815 trial) [42]. The updated data of IMCL-9815 trial for
subgroup analyses of patient and tumor factors suggested a
potential increased survival benefit from cetuximab in those
patients with early T stage and advanced N stage OPSCC, age
< 65 years, and high performance status [43]. Importantly,
the IMCL-9815 trial was not powered for this subgroup
analysis. Therefore these data could be ascribable to chance,
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Figure 2: Deintensification strategies.
but it should be noted that these characteristics are common
to patients with HPV-related disease and this finding has
encouraged research groups to test the use of cetuximab in
these patients. Two randomized noninferiority trials, the De-
ESCALaTE HPV trial and the RTOG 1016 trial, proposed
cetuximab for treatment deescalation strategy inHPV-related
OPSCC [44, 45]. The aim was to reduce standard cisplatin-
based CRT toxicity profile while preserving survival efficacy.
Final data analyses were published online in November 2018.
Contrary to expectations, replacing cisplatin with cetuximab
demonstrated a significantly detrimental impact on survival
end-points, in both trials. In light of these results, RT
plus cetuximab cannot be considered a deescalation strategy
to reduce toxicity while maintaining survival in patients
with HPV-related OPSCC. Cisplatin-based CRT remains the
standard of care.
Replace Cisplatin with Immune Check-Point Inhibitors. Dur-
ing the past few years, there has been an exciting development
of immunotherapy, especially check-point inhibitors in dif-
ferent human malignancies, including head and neck cancer
[46]. The immune check-point inhibitors represent a suc-
cessful immunotherapeutic approach, due to their peculiar
ability to target lymphocyte receptors, as opposed to target
therapy, such as cetuximab, that act directly on the tumor cells
[47]. They mainly include antiprogrammed death-1 (PD-1)
antibody and anticytotoxic T lymphocyte associated antigen
4 (CTLA-4) antibody. Nivolumab and pembrolizumab are
both anti-PD-1 antibody and are recommended as categories
1 and 2a, respectively, in recurrent and/or metastatic head
and neck cancer (nonnasopharyngeal cancer) if disease pro-
gresses on or after platinum-based chemotherapy [4]. Based
on phase III CheckMate 141 study (nivolumab) and phase Ib
KEYNOTE-012 trial (pembrolizumab), deintensification by
replacing cisplatinwith immune check-point inhibitors could
represent a promising strategy to achieve optimum disease
control with minimal long-term toxicities in HPV-related
OPSCC with favorable risk disease.
A phase II study with safety lead-in has been designed
to test safety, tolerability, and efficacy of anti-CTLA4 (ipili-
mumab) and anti-PD-1 (nivolumab) in combination with RT
up to 60Gy (2Gy per fraction) in patients with 8th edition
stages T1N2, T2N1-2, and T3N0-2 HPV-related OPSCC [48].
This study is not yet recruiting.
[To note, the potential role of RT combination with these
agents has recently been proposed in patients with HPV-related
OPSCC with smoking status > 10 pack-years, stage T1-2N2b-
N3, or ≤ 10 pack-years, stages T4N0-N3 or T1-3N3 [49].
The aim is to test the safety of nivolumab added to several
CRT regimens, including weekly cisplatin, high-dose cisplatin,
cetuximab, or IMRT alone. Final data collection for primary
outcome measures is estimated in March 2019.]
Enrolment in current trials of RT plus immune check-
point inhibitors in this patient population should be strongly
encouraged where possible.
4. Conclusions
At present, HPV-related OPSCC can be considered a distinct
disease primarily as a consequence of its anatomical location
and its viral aetiology. Its optimal treatment approach is still
not well-defined. For sure, HPV-related OPSCC is extremely
sensitive to radiation exposure and patients generally are
complete responders and long-term survivors. Therefore
over the years scientific interest has shifted to new stratagems
to potentially improve functional outcomes. Figure 2
Journal of Oncology 7
summarizes the main deintensification strategies, based
upon the published literature discussed above. We believe
that Figure 2 could add value to the indirect comparisons
of these methods. It must be appreciated that its bullet
points are suggestions to standardize protocols and develop
a gold-standard assessment panel. In fact, an important
question is how to best implement both intradisciplinary
and interdisciplinary into the current HPV-related OPSCC
management. Actually, the vast majority of clinical trial is
testing different approaches. Thus, in the coming years, there
will be a big data disorder that could delay the expected
change in the standard of care. It should emphasize the
importance of a trial design and the value to compare
what is already conformed to the standard. In addition,
accurate patient selection should be critical to optimal
implementation of a new strategy. Research groups should
endeavor to consider such observations to implement and
optimize clinical results. At present no changes in HPV-
related OPSCCmanagement should be made outside clinical
trials.
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